Patrick Campbell

An analysis of body weight and PBAC score from 121 women in Scotland suggests the presence of obesity could be linked to heavier menstrual bleeding and cause delays in womb lining repair.

An analysis of nearly 4.2 million patients from a birth registry indicates being born preterm was linked to a significantly higher risk of developing heart failure during childhood and a 42% greater risk of heart failure in adulthood.

While data indicates care has improved, a retrospective study from investigators at Columbia University suggests differences in rates of failure to rescue from severe maternal morbidity were a major contributor to the disparity in excess maternal mortality seen among Black women.

In the final portion of this video series, panelists discuss the implementation and use of telehealth in cardiology, but specifically the management of cholesterol disorders.

New data suggest injections of adipose-derived SVF cells could elicit wound closure in patients with nonhealing diabetic foot ulcers and, subsequently, reduce the need for amputation in this patient population.

Results of a 305-patient trial indicate ischemic leg pain could serve as a threshold for whether or not a patient with peripheral artery disease will see a meaningful improvement in walking score from their walking routine.

An analysis of the CLARIFY registry suggests patients with chronic coronary syndromes were 3 times more likely than the general population to have diabetes and these patients were at a greater risk of multiple adverse outcomes compared to their counterparts without diabetes.

Hear from Stephen Greene, MD, as he takes a deeper dive into a recent study he led comparing use of NYHA class vs. KCCQ-OS to capture changes in disease state among patients with heart failure with reduced ejection fraction.

An analysis of data from Cedars-Sinai medical centers suggests the shift to telemedicine during the pandemic led to a reduction in a number of diagnostic tests and medications prescribed when compared to rates of both during the pre-pandemic era.

In this portion of the panel discussion, panelists examine newer therapies for the treatment of lipid disorders. Included in this section are brief discussions around icosapent ethyl, inclisiran, and bempedoic acid. *This conversation occurred in February 2021 and regulatory approvals/decisions may have changed since filming.

An analysis of more than 4 million singleton births indicates children born at an early gestational age were at an increased risk of heart failure at multiple points throughout life when compared to their counterparts not considered preterm births.

Results of a randomized clinical trial suggest treatment with high-frequency spinal cord stimulation added to conventional medical management could lead to pain relief and improvements in quality of life among patients with refractory peripheral diabetic neuropathy.

An analysis of more than 8000 patients with HIV and hypertension suggests these patients may not be receiving the most efficacious antihypertensive agents and this could be placing these patients at increased risk of cardiovascular disease events or death.

An analysis of the DAPA-HF trial indicates the impact of dapagliflozin were consistent across both men and women receiving the SGLT2 inhibitor.

In this edition of Inside Cardiology, a trio of advisory board members discuss a series of case reports, upcoming and newly released therapies for lipid disorders, and use of telehealth for the management of patients.

Welcome to Inside Cardiology: Lipid Management 2021. This edition of Inside Cardiology features a discussion around lipidology led by Chief of Practical Cardiology's Editorial Advisory Board Guy Mintz, MD. Mintz is joined by fellow advisory board members Lucia Novak, CRNP, and Brett Nowlan, MD. In the first segment, panelists introduce themselves and examine the first case report in their 5-part discussion.

In this segment, panelists discuss their third and final case report. This case features a 63-year-old male classified as a very high-risk patient.

In this segment, panelists discuss their second case report. This case features a 60-year-old female classified as an extreme risk patient with diabetes.

Althera Pharmaceuticals announced the FDA approved rosuvastatin and ezetimibe (Roszet) as an adjunct to diet for lowering LDL-C in adults patients with primary non-familial hyperlipidemia or homozygous familial hypercholesterolemia.

Dr. Nisha Parikh provides additional insight into the AHA's latest scientific statement, which highlights the need for greater attention and emphasis on the impact of adverse pregnancy outcomes on cardiovascular risk in women.

An analysis of nearly 150 pregnant women presenting NY-based medical centers suggests prenatal exposure to endocrine-disrupting chemicals in plastics could increase odds of developing postpartum depression.

Announced in a statement by the FDA on April 1, the PCKS9 inhibitor alirocumab is now indicated as an add-on therapy for the treatment of homozygous familial hypercholesterolemia.

An analysis of 2-year data from the DRCR Retina Network's Protocol W study indicates anti-VEGF treatments can delay progression of NPDR to proliferative diabetic retinopathy but was not linked to improvements in visual acuity.

Results of the phase 2 PULSAR trial indicate sotatercept could be an effective adjunct to background medical therapy for reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

A study from Canada is calling for additional attention to paid to the screening, diagnosis, and treatment of primary aldosteronism in adult patients.

An analysis of DAPA-HF indicates the efficacy and safety profile of dapagliflozin was consistent regardless of patient sex, highlighting the potential of the SGLT2 inhibitor for heart failure patients.

An analysis of the YOUNG-MI registry suggests patients aged 50 or younger who suffer a heart attack were at nearly twice the risk of mortality if they had a diagnosis of a systemic inflammatory disease, such as rheumatoid arthritis and lupus, when compared to their counterparts without an inflammatory disease.

A phase 2 trial examining the effects of daily semaglutide over a 72-week period suggests the GLP1-RA could help patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) achieve NASH resolution.

An analysis of claims data by investigators at University of Pennsylvania indicates DOACs were associated with a 36% lower risk of stroke or systemic embolism and was also associated with a reduction in risk of major bleeding.

An analysis of the CHAMP-HF registry indicates KCCQ-OS was more sensitive at tracking changes in disease state among heart failure patients, indicating the importance of including patient-reported outcome measures in heart failure management.